Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Hervé Avet-Loiseau, Rafael Fonseca, David Siegel, Meletios A. Dimopoulos, Ivan Špička, Tamás Masszi, Roman Hájek, Laura Rosiñol, Vesselina Goranova-Marinova, Georgi Mihaylov, Vladimír Maisnar, Maria Victoria Mateos, Michael Wang, Ruben Niesvizky, Albert Oriol, Andrzej Jakubowiak, Jiri Minarik, Antonio Palumbo, William Bensinger, Vishal KukretiDina Ben-Yehuda, Alexander Keith Stewart, Mihaela Obreja, Philippe Moreau

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly improved with carfilzomib, lenalidomide, and dexamethasone (KRd), compared with lenalidomide and dexamethasone (Rd) in relapsed MM. This preplanned subgroup analysis of ASPIRE was conducted to evaluate KRd vs Rd by baseline cytogenetics according to fluorescence in situ hybridization. Of 417 patients with known cytogenetic risk status, 100 patients (24%) were categorized with high-risk cytogenetics (KRd, n548; Rd, n552) and 317 (76%) were categorized with standard-risk cytogenetics (KRd, n = 147; Rd, n = 170). For patients with high-risk cytogenetics, treatment with KRd resulted in a median PFS of 23.1 months, a 9-month improvement relative to treatment with Rd. For patients with standard-risk cytogenetics, treatment with KRd led to a 10-month improvement in median PFS vs Rd. The overall response rates for KRd vs Rd were 79.2% vs 59.6% (high-risk cytogenetics) and 91.2% vs 73.5% (standardrisk cytogenetics); approximately fivefold as many patients with high- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2% vs 5.8% and 38.1% vs 6.5%, respectively). KRd improved but did not abrogate the poor prognosis associated with high-risk cytogenetics. This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients.

Original languageEnglish (US)
Pages (from-to)1174-1180
Number of pages7
JournalBlood
Volume128
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Multiple Myeloma
Cytogenetics
Disease-Free Survival
Dexamethasone
carfilzomib
Standard of Care
Fluorescence In Situ Hybridization
Chromosome Aberrations
Therapeutics
Fluorescence
Survival

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., ... Moreau, P. (2016). Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, 128(9), 1174-1180. https://doi.org/10.1182/blood-2016-03-707596

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. / Avet-Loiseau, Hervé; Fonseca, Rafael; Siegel, David; Dimopoulos, Meletios A.; Špička, Ivan; Masszi, Tamás; Hájek, Roman; Rosiñol, Laura; Goranova-Marinova, Vesselina; Mihaylov, Georgi; Maisnar, Vladimír; Mateos, Maria Victoria; Wang, Michael; Niesvizky, Ruben; Oriol, Albert; Jakubowiak, Andrzej; Minarik, Jiri; Palumbo, Antonio; Bensinger, William; Kukreti, Vishal; Ben-Yehuda, Dina; Stewart, Alexander Keith; Obreja, Mihaela; Moreau, Philippe.

In: Blood, Vol. 128, No. 9, 01.09.2016, p. 1174-1180.

Research output: Contribution to journalArticle

Avet-Loiseau, H, Fonseca, R, Siegel, D, Dimopoulos, MA, Špička, I, Masszi, T, Hájek, R, Rosiñol, L, Goranova-Marinova, V, Mihaylov, G, Maisnar, V, Mateos, MV, Wang, M, Niesvizky, R, Oriol, A, Jakubowiak, A, Minarik, J, Palumbo, A, Bensinger, W, Kukreti, V, Ben-Yehuda, D, Stewart, AK, Obreja, M & Moreau, P 2016, 'Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma', Blood, vol. 128, no. 9, pp. 1174-1180. https://doi.org/10.1182/blood-2016-03-707596
Avet-Loiseau, Hervé ; Fonseca, Rafael ; Siegel, David ; Dimopoulos, Meletios A. ; Špička, Ivan ; Masszi, Tamás ; Hájek, Roman ; Rosiñol, Laura ; Goranova-Marinova, Vesselina ; Mihaylov, Georgi ; Maisnar, Vladimír ; Mateos, Maria Victoria ; Wang, Michael ; Niesvizky, Ruben ; Oriol, Albert ; Jakubowiak, Andrzej ; Minarik, Jiri ; Palumbo, Antonio ; Bensinger, William ; Kukreti, Vishal ; Ben-Yehuda, Dina ; Stewart, Alexander Keith ; Obreja, Mihaela ; Moreau, Philippe. / Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. In: Blood. 2016 ; Vol. 128, No. 9. pp. 1174-1180.
@article{5c68c769b52d4228bfdf07f1dcb5c6d0,
title = "Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma",
abstract = "The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly improved with carfilzomib, lenalidomide, and dexamethasone (KRd), compared with lenalidomide and dexamethasone (Rd) in relapsed MM. This preplanned subgroup analysis of ASPIRE was conducted to evaluate KRd vs Rd by baseline cytogenetics according to fluorescence in situ hybridization. Of 417 patients with known cytogenetic risk status, 100 patients (24{\%}) were categorized with high-risk cytogenetics (KRd, n548; Rd, n552) and 317 (76{\%}) were categorized with standard-risk cytogenetics (KRd, n = 147; Rd, n = 170). For patients with high-risk cytogenetics, treatment with KRd resulted in a median PFS of 23.1 months, a 9-month improvement relative to treatment with Rd. For patients with standard-risk cytogenetics, treatment with KRd led to a 10-month improvement in median PFS vs Rd. The overall response rates for KRd vs Rd were 79.2{\%} vs 59.6{\%} (high-risk cytogenetics) and 91.2{\%} vs 73.5{\%} (standardrisk cytogenetics); approximately fivefold as many patients with high- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2{\%} vs 5.8{\%} and 38.1{\%} vs 6.5{\%}, respectively). KRd improved but did not abrogate the poor prognosis associated with high-risk cytogenetics. This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients.",
author = "Herv{\'e} Avet-Loiseau and Rafael Fonseca and David Siegel and Dimopoulos, {Meletios A.} and Ivan Špička and Tam{\'a}s Masszi and Roman H{\'a}jek and Laura Rosi{\~n}ol and Vesselina Goranova-Marinova and Georgi Mihaylov and Vladim{\'i}r Maisnar and Mateos, {Maria Victoria} and Michael Wang and Ruben Niesvizky and Albert Oriol and Andrzej Jakubowiak and Jiri Minarik and Antonio Palumbo and William Bensinger and Vishal Kukreti and Dina Ben-Yehuda and Stewart, {Alexander Keith} and Mihaela Obreja and Philippe Moreau",
year = "2016",
month = "9",
day = "1",
doi = "10.1182/blood-2016-03-707596",
language = "English (US)",
volume = "128",
pages = "1174--1180",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

AU - Avet-Loiseau, Hervé

AU - Fonseca, Rafael

AU - Siegel, David

AU - Dimopoulos, Meletios A.

AU - Špička, Ivan

AU - Masszi, Tamás

AU - Hájek, Roman

AU - Rosiñol, Laura

AU - Goranova-Marinova, Vesselina

AU - Mihaylov, Georgi

AU - Maisnar, Vladimír

AU - Mateos, Maria Victoria

AU - Wang, Michael

AU - Niesvizky, Ruben

AU - Oriol, Albert

AU - Jakubowiak, Andrzej

AU - Minarik, Jiri

AU - Palumbo, Antonio

AU - Bensinger, William

AU - Kukreti, Vishal

AU - Ben-Yehuda, Dina

AU - Stewart, Alexander Keith

AU - Obreja, Mihaela

AU - Moreau, Philippe

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly improved with carfilzomib, lenalidomide, and dexamethasone (KRd), compared with lenalidomide and dexamethasone (Rd) in relapsed MM. This preplanned subgroup analysis of ASPIRE was conducted to evaluate KRd vs Rd by baseline cytogenetics according to fluorescence in situ hybridization. Of 417 patients with known cytogenetic risk status, 100 patients (24%) were categorized with high-risk cytogenetics (KRd, n548; Rd, n552) and 317 (76%) were categorized with standard-risk cytogenetics (KRd, n = 147; Rd, n = 170). For patients with high-risk cytogenetics, treatment with KRd resulted in a median PFS of 23.1 months, a 9-month improvement relative to treatment with Rd. For patients with standard-risk cytogenetics, treatment with KRd led to a 10-month improvement in median PFS vs Rd. The overall response rates for KRd vs Rd were 79.2% vs 59.6% (high-risk cytogenetics) and 91.2% vs 73.5% (standardrisk cytogenetics); approximately fivefold as many patients with high- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2% vs 5.8% and 38.1% vs 6.5%, respectively). KRd improved but did not abrogate the poor prognosis associated with high-risk cytogenetics. This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients.

AB - The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly improved with carfilzomib, lenalidomide, and dexamethasone (KRd), compared with lenalidomide and dexamethasone (Rd) in relapsed MM. This preplanned subgroup analysis of ASPIRE was conducted to evaluate KRd vs Rd by baseline cytogenetics according to fluorescence in situ hybridization. Of 417 patients with known cytogenetic risk status, 100 patients (24%) were categorized with high-risk cytogenetics (KRd, n548; Rd, n552) and 317 (76%) were categorized with standard-risk cytogenetics (KRd, n = 147; Rd, n = 170). For patients with high-risk cytogenetics, treatment with KRd resulted in a median PFS of 23.1 months, a 9-month improvement relative to treatment with Rd. For patients with standard-risk cytogenetics, treatment with KRd led to a 10-month improvement in median PFS vs Rd. The overall response rates for KRd vs Rd were 79.2% vs 59.6% (high-risk cytogenetics) and 91.2% vs 73.5% (standardrisk cytogenetics); approximately fivefold as many patients with high- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2% vs 5.8% and 38.1% vs 6.5%, respectively). KRd improved but did not abrogate the poor prognosis associated with high-risk cytogenetics. This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84987732917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987732917&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-03-707596

DO - 10.1182/blood-2016-03-707596

M3 - Article

C2 - 27439911

AN - SCOPUS:84987732917

VL - 128

SP - 1174

EP - 1180

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -